Retension Pharmaceuticals, Inc.

expected

Oct 9, 2026

per news reports

status

Filed with SEC

The expected listing date (Oct 9, 2026) comes from news reporting, not a regulatory filing — regulators publish a filing or approval date, not the day a company starts trading. See the source. It is replaced automatically if an official date is published.

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Underwriters (from filing)

Leerink Partners LLC, Guggenheim Securities, LLC, Oppenheimer & Co. Inc, Titan Partners Securities LLC

Overview

— AI-generated from the filing, see note below

Business overview

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and other cardiovascular diseases. Their lead product candidate, RTN-001, is engineered as a next-generation phosphodiesterase-5 (PDE-5) inhibitor aimed at reducing blood pressure through enhanced nitric oxide signaling. The company has conducted Phase 2 trials showing RTN-001's efficacy in reducing systolic and diastolic blood pressure while maintaining a favorable safety profile.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Targeting a significant unmet medical need in hypertension treatment
Experienced team with a focus on innovative drug development
Promising Phase 2 trial results for product candidate RTN-001

Risk factors

Potential for research and development delays
Dependence on the success of clinical trials
Competition from alternative therapies in the market

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The expected date is Oct 9, 2026. Underwriters on the deal include Leerink Partners LLC, Guggenheim Securities, LLC, Oppenheimer & Co. Inc, Titan Partners Securities LLC. Retension Pharmaceuticals, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Retension Pharmaceuticals, Inc..

Biotech IPOs United States IPOs Guggenheim Securities, LLC IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/retension-pharmaceuticals" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Retension Pharmaceuticals, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/retension-pharmaceuticals?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/retension-pharmaceuticals/opengraph-image

Attribution text

Retension Pharmaceuticals, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/retension-pharmaceuticals?utm_source=embed&utm_medium=text&utm_campaign=retension-pharmaceuticals

Track this IPO

Get emailed when Retension Pharmaceuticals, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

When is Retension Pharmaceuticals, Inc. expected to go public?

Retension Pharmaceuticals, Inc. is expected to list on Oct 9, 2026.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 5, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.